Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT04628494 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04628494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04628494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Lead sponsor
Genmab
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 13, 2021
Completion date
April 30, 2028
Enrollment
483 (actual)
Sites
186

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma